Your browser doesn't support javascript.
loading
[A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa]. / Un nuevo preparado de levodopa benserazida en parkinsonianos con fluctuaciones motoras refractarias a tratamientos con L-dopa standard.
Fernández Pardal, M M; Gatto, E; Micheli, F; Casas Parera, I; Diaz, S.
Afiliação
  • Fernández Pardal MM; División Neurología, Hospital de Clínicas José de San Martín, Facultad de Medicina, Universidad de Buenos Aires, Argentina.
Medicina (B Aires) ; 51(6): 561-7, 1991.
Article em Es | MEDLINE | ID: mdl-7476112
As Parkinson's disease worsens, many patients develop motor fluctuations which usually correlate directly or indirectly with L-dopa plasma levels. A new L-dopa-benserazide HBS preparation (Madopar) a control release pharmaceutical formulation which is activated when it contacts gastric fluid thus providing more stable L-dopa plasma levels, was assayed. Ten patients with a diagnosis of idiopathic Parkinson's disease and motor fluctuations otherwise unresponsive to conventional therapy were selected. The average age was 62 years and the duration of the disease 9 years. The motor status was evaluated on an hourly basis with the King's College Parkinson's disease rating scale; in addition, a nocturnal disability scale (Lees) was used. Out of the 10 patients, 2 dropped out within the first month due to worsening of parkinsonian signs, while 7 of the remainders preferred HBS preparation to the previous treatment. The number of off hours in this group was reduced by 58% and motor fluctuation became less severe. In only 3 cases was it possible to use HBS as monotherapy while in the rest standard L-dopa had to be added, specially as morning doses. The average L-dopa daily dose was increased by 36%. Unwanted effects included psychiatric disturbances in two (in one L-dopa dose had to be reduced) and epigastralgia in one. Our findings suggest that this L-dopa-benserazide control release may be considered an able therapeutic formulation in the control of motor fluctuations in Parkinson's disease.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Benserazida / Levodopa / Transtornos dos Movimentos Tipo de estudo: Etiology_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: Es Revista: Medicina (B Aires) Ano de publicação: 1991 Tipo de documento: Article País de afiliação: Argentina País de publicação: Argentina
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença de Parkinson / Benserazida / Levodopa / Transtornos dos Movimentos Tipo de estudo: Etiology_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: Es Revista: Medicina (B Aires) Ano de publicação: 1991 Tipo de documento: Article País de afiliação: Argentina País de publicação: Argentina